- Citations, last 5 years
- 0
- Works, last 5 years
- 0
- h-index
- 4
- Scientists listed
- 0
- Grants since 2016
- 8
Grants received
2020–2021 · research · R44
A polymeric biomaterial-based vaccine utilizing immunomodulatory agents and antigen for the amelioration of type 1 diabetes.
Benjamin Michael Looney · OneVax (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Biomaterial-Based Delivery of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes
Gregory Paul Marshall · OneVax (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Development of a dual microparticle platform vaccine system encapsulating immunomodulatory agents and antigen for the amelioration of type 1 diabetes
Gregory Paul Marshall · OneVax (United States) · funded by National Institutes of Health
2017–2019 · research · R21
Delivery of biomaterial-conjugated regulatory T Cells for the amelioration of Type 1 Diabetes
Gregory Paul Marshall · OneVax (United States) · funded by National Institutes of Health
2017–2018 · research · R41
Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes
Gregory Paul Marshall · OneVax (United States) · funded by National Institutes of Health
2017–2020 · research · R21
Delivery of biomaterial-conjugated regulatory T Cells for the amelioration of Type 1 Diabetes
Gregory Paul Marshall · OneVax (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Biomaterial-based delivery of Interleukin-2 to Regulatory T Cells for the amelioration of Type 1 Diabetes
Gregory Paul Marshall · OneVax (United States) · funded by National Institutes of Health
2017–2018 · research · R43
A novel biomaterial-based therapy utilizing auto-antigen and adjuvant for the amelioration of Type 1 Diabetes
Gregory Paul Marshall · OneVax (United States) · funded by National Institutes of Health
